Summary
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
History
Scopus BioPharma was founded in 2001 by a group of scientists and entrepreneurs. We began with a focus on developing cutting-edge treatments for cancer, but quickly expanded our research and development to include treatments for a wide variety of diseases. Over the years, we have grown to become a leading biopharmaceutical company, with operations in 20 countries around the globe.
Mission
At Scopus BioPharma, our mission is to discover, develop and deliver innovative solutions that help improve people's lives, while contributing to a sustainable environment.
Vision
We live with a passion to provide the best treatments possible— ensuring that people everywhere can access lifesaving medicines. We are focused on expanding the reach of our solutions by creating partnerships with entities in both developed and developing countries. Furthermore, we strive to be an innovator of both product and process, utilizing state-of-the-art technology to keep our pipeline of therapies strong.
Key Team
Dr. Alan D. Horsager Ph.D. (Pres?of?Immuno-Oncology and Pres & CEO of Duet BioTherapeutics)
Recognition and Awards
Scopus BioPharma has been recognized by several industry and private organizations for our achievements in the biopharmaceutical space. In 2019, we won the Fast Company Innovation Award for Leadership in BioTech. We have also received awards from the National Institutes of Health , the American Society for Clinical Oncology , and the World Health Organization . These awards serve as a testament to our commitment to making a positive impact on global health.
References
